Targeted anti-BCR-ABL+ ALL therapy may benefit the heartHanna Kirchhoff(Medizinische Hochschule Hannover), Denise Hilfiker‐Kleiner(Philipps University of Marburg)bioRxiv (Cold Spring Harbor Laboratory)June 6, 202110.1101/2021.06.04.447070Cited by 0SaveCiteExport RISWatch citationsRelated PapersImpaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease|PLoS ONE|2021|89Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages|Basic Research in Cardiology|2020|64Anthracycline-free tumor elimination in mice leads to functional and molecular cardiac recovery from cancer-induced alterations in contrast to long-lasting doxorubicin treatment effects|Basic Research in Cardiology|2021|16